Tenaya Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 10, 2025
TNYA$0.37-5.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
Balance Sheets
(In thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $4,323 | $45,681 |
| Short-term investments in marketable securities | 57,123 | 58,961 |
| Prepaid expenses and other current assets | 5,929 | 6,940 |
| Total current assets | 67,375 | 111,582 |
| Property and equipment, net | 35,858 | 43,277 |
| Operating lease right-of-use assets | 11,890 | 9,979 |
| Other noncurrent assets | 4,817 | 5,677 |
| Total assets | $119,940 | $170,515 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $5,162 | $5,630 |
| Accrued and other current liabilities | 8,035 | 12,784 |
| Operating lease liabilities, current | 2,778 | 4,319 |
| Total current liabilities | 15,975 | 22,733 |
| Operating lease liabilities, noncurrent | 10,830 | 8,105 |
| Other noncurrent liabilities | 281 | 253 |
| Total liabilities | 27,086 | 31,091 |
| Commitments and contingencies (Note 4) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 200,000,000 shares authorized as of December 31, 2024 and 2023; no shares issued and outstanding as of December 31, 2024 and 2023 | — | — |
| Common stock, $0.0001 par value; 1,000,000,000 shares authorized as of December 31, 2024 and 2023; 86,542,340 and 68,330,342 shares issued and outstanding as of December 31, 2024 and 2023 | 8 | 7 |
| Additional paid-in capital | 607,229 | 542,805 |
| Accumulated other comprehensive income (loss) | 28 | (106) |
| Accumulated deficit | (514,411) | (403,282) |
| Total stockholders’ equity | 92,854 | 139,424 |
| Total liabilities and stockholders’ equity | $119,940 | $170,515 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.